108 related articles for article (PubMed ID: 35384422)
1. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial.
Seo H; Kim H; Bae S; Park S; Chung H; Sung HS; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Son KY; Chong YP
Infect Chemother; 2022 Mar; 54(1):102-113. PubMed ID: 35384422
[TBL] [Abstract][Full Text] [Related]
2. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.
Reiersen AM; Mattar C; Bender Ignacio RA; Boulware DR; Lee TC; Hess R; Lankowski AJ; McDonald EG; Miller JP; Powderly WG; Pullen MF; Rado JT; Rich MW; Schiffer JT; Schweiger J; Spivak AM; Stevens A; Vigod SN; Agarwal P; Yang L; Yingling M; Gettinger TR; Zorumski CF; Lenze EJ
Open Forum Infect Dis; 2023 Aug; 10(8):ofad419. PubMed ID: 37622035
[TBL] [Abstract][Full Text] [Related]
5. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
6. Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
; Naggie S
medRxiv; 2023 Sep; ():. PubMed ID: 37745371
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
9. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
medRxiv; 2022 Nov; ():. PubMed ID: 36299427
[TBL] [Abstract][Full Text] [Related]
10. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
[TBL] [Abstract][Full Text] [Related]
11. Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.
Tsiakalos A; Ziakas PD; Polyzou E; Schinas G; Akinosoglou K
Microorganisms; 2023 Aug; 11(8):. PubMed ID: 37630633
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
15. Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Tu YK; Yang SN; Hsu TW; Yeh TC; Liang CS
Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901099
[TBL] [Abstract][Full Text] [Related]
16. Operation and Management of Seoul Metropolitan City Community Treatment Center for Mild Condition COVID-19 Patients.
Lee SY; Song KJ; Lim CS; Kim BG; Chai YJ; Lee JK; Kim SH; Lim HJ
J Korean Med Sci; 2020 Oct; 35(40):e367. PubMed ID: 33075858
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Ziaei A; Davoodian P; Dadvand H; Safa O; Hassanipour S; Omidi M; Masjedi M; Mahmoudikia F; Rafiee B; Fathalipour M
Trials; 2020 Oct; 21(1):882. PubMed ID: 33106171
[TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
[TBL] [Abstract][Full Text] [Related]
20. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P
Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]